Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

564
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
564
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

957
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
957
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

538
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
538
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

33
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
33

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)].

Revue des maladies respiratoires·2025
Same author

[Low-dose methotrexate: Indications and side effects, particularly in cases of diffuse interstitial pneumonia].

Revue des maladies respiratoires·2024
Same author

Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis].

Revue des maladies respiratoires·2023
Same author

[J2R 2022 back in Reims].

Revue des maladies respiratoires·2023
Same author

[Adipocytes, adipokines and metabolic alterations in pulmonary fibrosis].

Revue des maladies respiratoires·2023

Related Experiment Video

Updated: May 6, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
06:29

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques

Published on: June 11, 2019

10.4K

[Focus on mediastinal Castleman disease].

R Borie1, M Riquet2, C Danel3

  • 1Service de pneumologie A, centre de compétences maladies rares pulmonaires, hôpital Bichat, AP-HP, 16, rue Henri-Huchard, 75877 Paris cedex 18, France.

Revue De Pneumologie Clinique
|November 12, 2013
PubMed
Summary

Castleman disease, a rare lymph node condition, often presents as a localized hyaline vascular form in young adults, frequently asymptomatic. Complete surgical resection is the primary treatment for this Castleman disease variant.

Keywords:
BronchioliteBronchiolitisCastleman diseaseImmunoglobulinImmunoglobulineParaneoplasic pemphigusPemphigus paranéoplasiqueRituximabTransplantation

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Related Experiment Videos

Last Updated: May 6, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
06:29

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques

Published on: June 11, 2019

10.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Area of Science:

  • Oncology
  • Pathology
  • Immunology

Background:

  • Castleman disease encompasses diverse clinical presentations affecting lymph nodes.
  • The hyaline vascular variant is the most common histology.
  • This localized form typically affects young adults, with mediastinal involvement in one-third of cases.

Purpose of the Study:

  • To describe the characteristics and management of the hyaline vascular variant of Castleman disease.
  • To highlight associated conditions such as paraneoplastic pemphigus.
  • To outline treatment strategies for localized Castleman disease.

Main Methods:

  • Review of clinical presentations and histological findings in Castleman disease.
  • Analysis of treatment outcomes for the hyaline vascular form.
  • Evaluation of perioperative management, particularly for associated paraneoplastic pemphigus.

Main Results:

  • The hyaline vascular Castleman disease is often asymptomatic.
  • Paraneoplastic pemphigus is a noted complication.
  • Complete surgical resection is the standard management approach.

Conclusions:

  • The hyaline vascular Castleman disease is a distinct entity requiring surgical resection.
  • Management may involve immunomodulating treatments for associated paraneoplastic pemphigus, especially with bronchial involvement.